China is tightening oversight of investigator-initiated trials (ITTs), a model that has helped accelerate trial starts but has increasingly drawn scrutiny. A STAT+ report said new enforcement is being added even as U.S. stakeholders seek ways to replicate China’s faster first-in-human timelines. The article frames ITTs as a system previously permitted to start without NMPA sign-off, enabling physicians to run studies more quickly and contributing to rapid translation and approvals. However, concerns raised include patient safety, transparency, and intellectual property practices. For biotech developers and CROs with China-facing trial plans, the shift signals potential changes to submission readiness timelines, governance expectations, and operational compliance requirements. The direction of travel may affect feasibility strategies for global early-phase programs competing for speed versus regulatory certainty.